《自发性早产风险蛋白质生物标志物的分析验证》[临床质谱学3（2017）25 - 38]的勘误
Corrigendum to "Analytical validation of protein biomarkers for risk of spontaneous preterm birth" [Clin. Mass Spectrom. 3 (2017) 25-38].
作者信息
Bradford Chad, Severinsen Rob, Pugmire Trina, Rasmussen Matison, Stoddard Kathryn, Uemura Yuta, Wheelwright Spencer, Mentinova Marija, Chelsky Daniel, Hunsucker Stephen W, Kearney Paul, Hickok Durlin, Fleischer Tracey C, Ichetovkin Ilia, Boniface J Jay, Critchfield Gregory C, Peltier John M
机构信息
Sera Prognostics, Inc., 2749 East Parleys Way, Suite 200, Salt Lake City, UT 84109, USA.
Caprion Biosciences, 201 Avenue Président Kennedy, Suite 3900, Montréal, Québec H2X 3Y7, Canada.
出版信息
J Mass Spectrom Adv Clin Lab. 2022 Aug 9;25:71. doi: 10.1016/j.jmsacl.2022.07.007. eCollection 2022 Aug.
Abstract
[This corrects the article DOI: 10.1016/j.clinms.2017.06.002.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.clinms.2017.06.002。]
相似文献
1
Corrigendum to "Analytical validation of protein biomarkers for risk of spontaneous preterm birth" [Clin. Mass Spectrom. 3 (2017) 25-38].《自发性早产风险蛋白质生物标志物的分析验证》[临床质谱学3（2017）25 - 38]的勘误
J Mass Spectrom Adv Clin Lab. 2022 Aug 9;25:71. doi: 10.1016/j.jmsacl.2022.07.007. eCollection 2022 Aug.
2
Corrigendum to "Instability of 7-aminoclonazepam in frozen storage conditions" [Clin. Mass Spectrom. 9 (2018) 23-24].《“7-氨基氯硝西泮在冷冻储存条件下的不稳定性”勘误》[《临床质谱学》9(2018)23 - 24]
J Mass Spectrom Adv Clin Lab. 2022 Sep 24;26:34. doi: 10.1016/j.jmsacl.2022.09.006. eCollection 2022 Nov.
3
Corrigendum to "Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs" [Clin. Mass Spectrom. 14(Part A) (2019) 34-45].《抗结核药物治疗药物监测的质谱分析》勘误[临床质谱学14（A部分）（2019年）34 - 45页]
J Mass Spectrom Adv Clin Lab. 2022 Aug 13;25:72. doi: 10.1016/j.jmsacl.2022.08.001. eCollection 2022 Aug.
4
Corrigendum to "Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease" [Clin. Mass Spectrom. 14 (Part B) (2019) 74-82].《脑脊液中tau蛋白与肽的比率用于改善阿尔茨海默病诊断分类》的勘误 [临床质谱学。14 (B部分) (2019) 74 - 82]
J Mass Spectrom Adv Clin Lab. 2022 Sep 28;26:35. doi: 10.1016/j.jmsacl.2022.08.002. eCollection 2022 Nov.
5
Corrigendum to "Observation of a positive interference in LC-MS/MS measurement of d6-25-OH-vitamin D3" [Clin. Mass Spectrom. 3 (2017) 22-24].《“d6 - 25 - 羟基维生素D3的液相色谱 - 串联质谱测定中的正干扰观察”勘误》[临床质谱学 3 (2017) 22 - 24]
J Mass Spectrom Adv Clin Lab. 2022 Sep 9;26:20. doi: 10.1016/j.jmsacl.2022.09.002. eCollection 2022 Nov.
6
Corrigendum to "Manipulating trypsin digestion conditions to accelerate proteolysis and simplify digestion workflows in development of protein mass spectrometric assays for the clinical laboratory" [Clin. Mass Spectrom. 6C (2018) 1-12].《“在临床实验室蛋白质质谱分析方法开发中操控胰蛋白酶消化条件以加速蛋白水解并简化消化工作流程”的勘误》[临床质谱学 6C（2018 年）1 - 12]
Clin Mass Spectrom. 2018 Aug 30;10:33-34. doi: 10.1016/j.clinms.2018.08.005. eCollection 2018 Dec.
7
Corrigendum to "Migration from RIA to LC-MS/MS for aldosterone determination: Implications for clinical practice and determination of plasma and urine reference range intervals in a cohort of healthy Belgian subjects" [Clin. Mass Spectrom. 9 (2018) 7-17].《从放射免疫分析迁移至液相色谱-串联质谱法测定醛固酮：对临床实践的影响以及一组健康比利时受试者血浆和尿液参考范围区间的测定》勘误 [临床质谱学 9 (2018) 7 - 17]
J Mass Spectrom Adv Clin Lab. 2022 Oct 26;26:47. doi: 10.1016/j.jmsacl.2022.10.001. eCollection 2022 Nov.
8
Corrigendum to "Development and validation of a multiplexed LC-MS/MS ketone body assay for clinical diagnostics" [J. Mass Spectrom. Adv. Clin. Lab 31 (2024) 49-58].《用于临床诊断的多重液相色谱-串联质谱酮体检测方法的开发与验证》的勘误 [《质谱学报：临床实验室进展》31 (2024) 49 - 58]
J Mass Spectrom Adv Clin Lab. 2024 Jul 17;33:21. doi: 10.1016/j.jmsacl.2024.07.001. eCollection 2024 Aug.
9
Erratum regarding missing Declaration of Competing Interest Statements in previously published articles.关于之前发表文章中缺失利益冲突声明的勘误。
J Mass Spectrom Adv Clin Lab. 2021 Jan 29;20:48. doi: 10.1016/j.jmsacl.2021.01.001. eCollection 2021 Apr.
10
Corrigendum to "Is IVF/ICSI an Independent Risk Factor for Spontaneous Preterm Birth in Singletons? A Population-Based Cohort Study".《体外受精/卵胞浆内单精子注射是否为单胎自发性早产的独立危险因素？一项基于人群的队列研究》勘误
Biomed Res Int. 2019 Apr 3;2019:4940314. doi: 10.1155/2019/4940314. eCollection 2019.
引用本文的文献
1
Neonatal Outcomes after Maternal Biomarker-Guided Preterm Birth Intervention: The AVERT PRETERM Trial.母亲生物标志物引导的早产干预后的新生儿结局：AVERT早产试验
Diagnostics (Basel). 2024 Jul 9;14(14):1462. doi: 10.3390/diagnostics14141462.
2
Better Estimation of Spontaneous Preterm Birth Prediction Performance through Improved Gestational Age Dating.通过改进孕周估算来更好地评估自发性早产预测性能。
J Clin Med. 2022 May 19;11(10):2885. doi: 10.3390/jcm11102885.
3
Is there a maternal blood biomarker that can predict spontaneous preterm birth prior to labour onset? A systematic review.是否存在一种母体血液生物标志物可以在分娩发作前预测自发性早产？系统评价。
PLoS One. 2022 Apr 4;17(4):e0265853. doi: 10.1371/journal.pone.0265853. eCollection 2022.
4
Clinical Validation of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth and Associated Clinical Outcomes: A Replication Study.蛋白质组学生物标志物阈值对自发性早产风险增加及相关临床结局的临床验证：一项重复研究
J Clin Med. 2021 Oct 29;10(21):5088. doi: 10.3390/jcm10215088.
5
Design and Characterization of a Novel Blood Collection and Transportation Device for Proteomic Applications.用于蛋白质组学应用的新型血液采集与运输装置的设计与表征
Diagnostics (Basel). 2020 Dec 2;10(12):1032. doi: 10.3390/diagnostics10121032.
6
Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.用于恶性胸膜间皮瘤的基于血液的靶向蛋白质组学标志物的验证。
Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):1973-1982. doi: 10.1158/1055-9965.EPI-20-0543. Epub 2020 Jul 30.
7
The building blocks of successful translation of proteomics to the clinic.蛋白质组学向临床转化成功的基石。
Curr Opin Biotechnol. 2018 Jun;51:123-129. doi: 10.1016/j.copbio.2017.12.011. Epub 2018 Feb 7.
Zotero 插件